bims-cesemi Biomed News
on Cellular senescence and mitochondria
Issue of 2026–11–08
four papers selected by
Julio Cesar Cardenas, Universidad Mayor



  1. Elife. 2026 Nov 04. pii: RP107123. [Epub ahead of print]14
      The cell NAD+/NADH ratio can constrain biomass synthesis and influence proliferation in nutrient-limited environments. However, which cell processes regulate the NAD+/NADH ratio is not known. Here, we find that some cancer cells elevate the NAD+/NADH ratio in response to serine deprivation by increasing mitochondrial respiration. Cancer cells that elevate mitochondrial respiration have higher serine production and proliferation in serine-limiting conditions than cells with no mitochondrial respiration response, independent of serine synthesis enzyme expression. Increases in mitochondrial respiration and the NAD+/NADH ratio promote serine synthesis regardless of whether serine is environmentally limiting. Lipid deprivation can increase the NAD+/NADH ratio via mitochondrial respiration in some cells, including cells that do not increase respiration following serine deprivation. Thus, in cancer cells where lipid depletion raises the NAD+/NADH ratio, proliferation in serine-depleted environments improves when lipids are also depleted. Taken together, these data suggest that changes in mitochondrial respiration in response to nutrient deprivation can influence the NAD+/NADH ratio in a cell-specific manner to impact oxidative biomass synthesis and proliferation. Given the complexity of tumor microenvironments, this work provides a metabolic framework for understanding how levels of more than one environmental nutrient affect cancer cell proliferation.
    Keywords:  NAD+/NADH ratio; biochemistry; cancer biology; cancer metabolism; chemical biology; human; lipid depletion; mitochondria; serine
    DOI:  https://doi.org/10.7554/eLife.107123
  2. Cell Rep. 2026 Nov 06. pii: S2211-1247(26)01346-X. [Epub ahead of print]45(11): 118267
      Multiple myeloma is a plasma cell malignancy that develops within the bone marrow. The bone marrow metabolome is altered in myeloma, with implications for malignant cell growth. Here, the impact of elevated bone marrow levels of the tricarboxylic acid (TCA) cycle metabolite, succinate, was interrogated. Succinate was found to promote proliferation of several myeloma cell lines. This was linked to its uptake and oxidation in the TCA cycle, as indicated by increased ATP-coupled mitochondrial respiration and incorporation of succinate-derived carbons into downstream TCA cycle intermediates, which also occurs in primary myeloma cells. Succinate-driven proliferation was dependent upon mitochondrial oxidative phosphorylation and abrogated by ATP synthase inhibition. Furthermore, interrogation of large-scale transcriptomic data identified that elevated expression of a mitochondrial succinate transporter associates with accelerated disease progression in myeloma, indicating this mechanism may promote plasma cell growth in vivo and highlighting a target for therapeutic intervention.
    Keywords:  CP: cancer; CP: metabolism; anti-tumour immunity; cancer; cancer metabolism; immunometabolism; metabolism; metabolites; mitochondria; multiple myeloma; succinate
    DOI:  https://doi.org/10.1016/j.celrep.2026.118267
  3. Cell. 2026 Nov 02. pii: S0092-8674(26)01139-6. [Epub ahead of print]
      When subject to damage or stress, cells develop responses in order to maintain tissue homeostasis. Two such responses are ferroptosis and cellular senescence, but how cells decide between these outcomes remains unclear. Here, we show that senescent cells increase import and membrane levels of multiple polyunsaturated fatty acids (PUFAs), but a specific intermediate PUFA, dihomo-gamma-linolenic acid (DGLA, 20:3ω-6), is reduced. Exogenous repletion of DGLA instead results in cell death by ferroptosis. Senescent cells manifest additional features associated with ferroptosis, including labile iron and expression of lipoxygenases as well as low-level membrane peroxidation. Oral DGLA supplementation lowers markers of senescence in aged mice and improves age-related functional outcomes. Finally, obese humans with lowered DGLA desaturation rates have lower markers of adipose tissue senescence. Together, our data implicate shifts in PUFA metabolism as a driver of decisions between senescence and ferroptosis.
    Keywords:  DGLA; PUFA; aging; desaturation; ferroptosis; lipid peroxidation; metabolism; obesity; senescence; senolytic
    DOI:  https://doi.org/10.1016/j.cell.2026.09.036
  4. Biochim Biophys Acta Rev Cancer. 2026 Nov 03. pii: S0304-419X(26)00218-0. [Epub ahead of print]1881(6): 189746
      Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains largely incurable because of its marked cellular heterogeneity, limited drug delivery, and rapid development of resistance to temozolomide (TMZ). Beyond its cytotoxic activity, TMZ induces genotoxic and oxidative stress and exerts strong selective pressure, potentially promoting adaptive states in GBM cells that survive chemotherapy. These adaptive responses are heterogeneous and context-dependent and may not only promote tumor cell intrinsic resistance but also strongly reshape the surrounding tumor microenvironment. This review focuses on residual tumor cells that survive TMZ-induced stress and examines how their adaptive responses contribute to treatment resistance and may be sustained by reciprocal interactions with the tumor microenvironment. Specifically, it integrates findings on stem-like enrichment, inflammatory and redox signalling, altered extracellular vesicle release, therapy-induced senescence, and extracellular matrix remodelling, examining how these processes may reinforce one another and link tumor cell survival to signals that influence neighbouring malignant and non-malignant cells. Findings are interpreted within their experimental context, distinguishing evidence from in vitro studies, animal models, and patient samples. This integrated framework provides a rationale for investigating TMZ-based strategies aimed not only at eliminating surviving GBM cells but also at limiting their ability to promote a microenvironment that supports tumor persistence and resistance.
    Keywords:  Chemotherapy; Glioblastoma; Glioma stem cells; Temozolomide; Therapy resistance; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189746